Investors

Press Releases

Date Title View
Toggle Summary Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Third Quarter 2005 Financial Results
Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Third Quarter 2005 Financial Results CAMBRIDGE, Mass., Oct. 14 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar
View HTML
Toggle Summary Momenta Pharmaceuticals to Present at UBS Global Life Sciences Conference
Momenta Pharmaceuticals to Present at UBS Global Life Sciences Conference CAMBRIDGE, Mass., Sept. 22 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology, announced today that Alan L.
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Abbreviated New Drug Application Filing for M-Enoxaparin
Momenta Pharmaceuticals Announces Abbreviated New Drug Application Filing for M-Enoxaparin CAMBRIDGE, Mass., Aug. 30 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), announced today that an Abbreviated New Drug Application (ANDA) seeking marketing approval of M-Enoxaparin has
View HTML
Toggle Summary Momenta Pharmaceuticals Reports Financial Results for the Second Quarter of 2005
Momenta Pharmaceuticals Reports Financial Results for the Second Quarter of 2005 On Track to File ANDA for M-Enoxaparin in August CAMBRIDGE, Mass., Aug. 10 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Second Quarter 2005 Financial Results
Momenta Pharmaceuticals Announces Date of Earnings Release and Conference Call for Second Quarter 2005 Financial Results CAMBRIDGE, Mass., July 25 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Pricing of Public Offering of 4,827,300 Shares of Common Stock
Momenta Pharmaceuticals Announces Pricing of Public Offering of 4,827,300 Shares of Common Stock CAMBRIDGE, Mass., July 21 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) today announced the pricing of a public offering of 4,827,300 shares of its common stock at $27.02 per
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Public Offering of 4 Million Shares of Common Stock
Momenta Pharmaceuticals Announces Public Offering of 4 Million Shares of Common Stock CAMBRIDGE, Mass., July 18 /PRNewswire-FirstCall/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA) announced today its intention to publicly offer 4 million shares of its common stock pursuant to its effective shelf
View HTML
Toggle Summary Momenta Pharmaceuticals to Present at the Bear Stearns Boston Biotech Conference
Momenta Pharmaceuticals to Present at the Bear Stearns Boston Biotech Conference CAMBRIDGE, Mass., June 24, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing technology,
View HTML
Toggle Summary Momenta Pharmaceuticals Announces Appointment of Peter Barrett as Chairman of Board of Directors
Momenta Pharmaceuticals Announces Appointment of Peter Barrett as Chairman of Board of Directors Appointment of Non-Executive Chairman in Alignment with Good Governance Practices CAMBRIDGE, Mass., June 13, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc.
View HTML
Toggle Summary Momenta Pharmaceuticals to Present at The 2005 Pacific Growth Equities Life Sciences Growth Conference
Momenta Pharmaceuticals to Present at The 2005 Pacific Growth Equities Life Sciences Growth Conference CAMBRIDGE, Mass., June 6, 2005 /PRNewswire-FirstCall via COMTEX/ -- Momenta Pharmaceuticals, Inc. (Nasdaq: MNTA), a biotechnology company developing drugs based on its proprietary sugar sequencing
View HTML